biostudies-literatureUnknown42(9)Nicolle R<h4>Purpose</h4>GemPred, a transcriptomic signature predictive of the efficacy of adjuvant gemcitabine (GEM), was developed from cell lines and organoids and validated retrospectively. The phase III PRODIGE-24/CCTG PA6 trial has demonstrated the superiority of modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) over GEM as adjuvant therapy in patients with resected pancreatic ductal adenocarcinoma at the expense of higher toxicity. We evaluated the potential predictive value of GemPred in this population.<h4>Patients and methods</h4>Routine formalin-fixed paraffin-embedded surgical specimens of 350 patients were retrieved for RNA sequencing and GemPred prediction (167 in the GEM arm and 183 in the mFOLFIRINOX [mFFX] arm). Survival analyses were stratified by reseJournal of clinical oncology : official journal of the American Society of Clinical Oncology1067-1076https://www.ebi.ac.uk/biostudies/studies/S-EPMC10950182biostudies-literaturePrediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.PMC10950182Mitry EDusetti NArtru PWei ABen Abdelghani MBiagi JHarle AMauduit MHammel PCros JIovanna JLambert ARenouf DJBachet JBRebours VTurpin ANicolle RMonard LConroy TLopez AFrancois EfalsePrediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.<h4>Purpose</h4>GemPred, a transcriptomic signature predictive of the efficacy of adjuvant gemcitabine (GEM), was developed from cell lines and organoids and validated retrospectively. The phase III PRODIGE-24/CCTG PA6 trial has demonstrated the superiority of modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) over GEM as adjuvant therapy in patients with resected pancreatic ductal adenocarcinoma at the expense of higher toxicity. We evaluated the potential predictive value of GemPred in this population.<h4>Patients and methods</h4>Routine formalin-fixed paraffin-embedded surgical specimens of 350 patients were retrieved for RNA sequencing and GemPred prediction (167 in the GEM arm and 183 in the mFOLFIRINOX [mFFX] arm). Survival analyses were stratified by rese2024-01-01T00:00:00Z2024 Mar2025-04-19T22:03:05.842Z2025-04-19T22:03:05.842ZS-EPMC109501823796331310.1200/JCO.22.02668